IMBALANCED MACHINE LEARNING CLASSIFICATION MODELS FOR REMOVAL BIOSIMILAR DRUGS AND INCREASED ACTIVITY IN PATIENTS WITH RHEUMATIC DISEASES

<p>Objective: Predict long-term disease worsening and the removal of biosimilar medication in patients with rheumatic diseases.</p><p>Methodology: Observational, retrospective, and descriptive study. Review of a database of patients with immune-mediated inflammatory rheumatic diseases. Disease worsening and removing biosimilars are imbalanced variables, that require using imbalanced machine learning models selected based on their superior f1-scores and great accuracy. Previously, we selected the most important variables using mutual information tests.</p><p>Results: The best imbalanced machine learning models to predict disease worsening and the removal of the biosimilar obtained f1-scores of 0.52 and 0.63, respectively. Both models are decision trees. In the first one, two important factors are switching of biosimilar and age, and in the second, the relevant variables are optimization and the value of the initial CRP.&nbsp;</p><p>Conclusions: Biosimilar drugs do not always work well for rheumatic diseases. We obtained two imbalanced machine learning models to detect those cases, where the drug should be removed or where the activity of the disease increases from low to high. Our decision trees use variables, such as age or switching, not considered in previous studies.</p>